#SFHS2608199AOrder of April 2, 2026 amending the list of reimbursable pharmaceutical specialties
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law updates the French reimbursable medicines list by adding a treatment for a rare condition known as hyperargininemia. This is relevant for patients and healthcare providers, especially those involved with genetic disorders. The law comes into effect 15 days after its publication.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Addition of pegzilarginase for hyperargininemia treatment to the reimbursable list
- Law takes effect 15 days after publication
Obligations
What this law requires
Add LOARGYS (pegzilarginase) 5mg/ml solution injectable/pour perfusion (CIP 34009 302 832 8 8) to the list of reimbursable pharmaceutical specialties for social insurance beneficiaries
Restrict reimbursement of LOARGYS exclusively to treatment of arginase 1 deficiency (ARG1-D/hyperargininemia in patients aged 2 years and older (adults, adolescents, and children)
Implement the reimbursement modification 15 days following publication in the Journal officiel de la République française
Publish this Order in the Journal officiel de la République française